Search results for "unstable angina"

showing 10 items of 80 documents

Platelet Function During Ticlopidine and Eicosapentaenoic Acid Administration in Patients with Coronary Heart Disease

2010

Antiplatelet drugs have been reported to be useful in unstable angina. This study was designed to investigate the effects of simultaneous administration of ticlopidine and eicosapentaenoic acid (EPA) on platelet function in coronary heart disease (CHD) patients. Ticlopidine significantly reduced platelet aggregation induced by ADP and collagen with no effect on arachidonate metabolism. The aggregation responses to collagen, ADP and arachidonate were not altered significantly by EPA (as fish oil) intake whereas thromboxane A(2) formation was reduced, but not completely inhibited. Combined therapy seems to achieve a more marked degree of inhibition of aggregation together with a fall in the u…

medicine.medical_specialtyUnstable anginabusiness.industryMetaboliteHematologyGeneral MedicinePharmacologyFish oilmedicine.diseaseEicosapentaenoic acidchemistry.chemical_compoundThromboxane A2chemistryInternal medicinemedicineCardiologyPlateletPlatelet activationTiclopidinebusinessmedicine.drugPlatelets
researchProduct

Coronary Angioplasty in Unstable Angina

1990

When Gruntzig introduced the revolutionary method of percutaneous transluminal coronary angioplasty (PTCA) for the treatment of coronary artery stenoses, he initially devoted this technique only to patients with stable angina pectoris [8]. Very soon, however, it was discovered simultaneously by Williams et al. [19] and by our group [12] that this method can also be used in patients with unstable angina pectoris. The earliest experiences with PTCA in 1980 were published by our two groups (Table 1). In these series the average degree of stenosis was somewhat lower than that today, while the residual stenosis after treatment was slightly higher. The very rough balloons and guiding catheters av…

medicine.medical_specialtyUnstable anginabusiness.industrymedicine.medical_treatmentResidual stenosismedicine.diseaseStable anginaStenosisCathetermedicine.anatomical_structureAngioplastyInternal medicinemedicineCardiologyIn patientcardiovascular diseasesbusinessArtery
researchProduct

417 SOLUBLE CELLULAR ADHESION MOLECULES, MYELOPEROXIDASE, AND NEOPTERIN IN METABOLIC SYNDROME PATIENTS WITH STABLE AND UNSTABLE ANGINA PECTORIS

2011

medicine.medical_specialtybiologyCell adhesion moleculeUnstable anginaNeopterinGeneral Medicinemedicine.diseasechemistry.chemical_compoundEndocrinologychemistryInternal medicineMyeloperoxidaseInternal Medicinemedicinebiology.proteinMetabolic syndromeCardiology and Cardiovascular MedicineAtherosclerosis Supplements
researchProduct

Cystatin C levels are decreased in acute myocardial infarction

2005

Background: Cystatin C is the most abundant protease inhibitor in the plasma. Low plasma levels have been found in patients with aortic aneurysms and they seem correlated with the extension of the aortic lesions in early aneurysms detected by ultrasonography. Methods: In this study, plasma levels of cystatin C have been investigated in patients with acute myocardial infarction (AMI), unstable angina and controls. The effect on plasma levels of the G73A polymorphism of the CST3 gene has been also evaluated. Results: Patients with acute myocardial infarction showed significantly lower levels of cystatin C compared to unstable angina and controls, but levels were nearly normal in a week after …

medicine.medical_specialtybiologyCholesterolbusiness.industryUnstable anginaAcute-phase proteinurologic and male genital diseasesmedicine.diseaseCoronary artery diseasechemistry.chemical_compoundEndocrinologyCystatin CchemistryInternal medicineBlood plasmaCardiologymedicinebiology.proteincardiovascular diseasesGene polymorphismMyocardial infarctionCardiology and Cardiovascular MedicinebusinessInternational Journal of Cardiology
researchProduct

Aktuelle Komplikationsrate der perkutanen transluminalen Koronarangioplastie bei stabiler und unstabiler Angina

2008

During a four-year period (1983-1986) percutaneous transluminal coronary angioplasty (PTCA) was performed on 930 patients with stable or unstable angina with a mortality rate of 0.4%. A transmural myocardial infarct developed in 1.1% and 1.0% of patients required an urgent aorto-coronary bypass. Thus the total rate of severe cardiac complications was 2.5%. Compared with the years 1983-1985, there was in 1986 a significant fall in the number of deaths and of myocardial infarcts from 2.2% to 0.5% (P less than 0.05), while there was a nonsignificant increase in emergency coronary bypass surgery from 0.7 to 1.3%. Patients with unstable angina compared with those with stable angina had a signifi…

medicine.medical_specialtybusiness.industryUnstable anginaIncidence (epidemiology)Mortality ratemedicine.medical_treatmentInfarctionGeneral Medicinemedicine.diseaseAnginaBypass surgeryInternal medicineAngioplastyCardiologyMedicinecardiovascular diseasesMyocardial infarctionbusinessDMW - Deutsche Medizinische Wochenschrift
researchProduct

Antithrombotic therapy in acute coronary syndromes

2000

Current therapy of acute coronary syndromes (i.e., unstable angina and non-Q-wave myocardial infarction, Q-wave myocardial infarction) consists of thrombolytic, anti-platelet, and anti-coagulant therapy. In most cases of acute coronary syndromes, the pathogenesis is a mural thrombus formation on a ruptured or eroded atherosclerotic plaque. Both platelets and thrombin play an essential role in the pathophysiology of acute coronary syndromes. Aspirin and heparin are essential treatments for patients with acute coronary syndromes. Novel thrombin and platelet inhibitors have been developed and demonstrated useful effects for improving both acute and long-term clinical outcomes in acute coronary…

medicine.medical_specialtybusiness.industryUnstable anginaReteplaseTirofibanHeparinClopidogrelmedicine.diseaseInternal medicinemedicineAbciximabEptifibatideCardiologyMyocardial infarctionbusinessmedicine.drug
researchProduct

Interventional cardiology: Differences in the morphology of unstable and stable coronary lesions and their impact on the mechanisms of angioplasty. A…

1996

The aim of this study was to compare the morphology of stable and unstable coronary lesions using intravascular ultrasound in patients undergoing coronary balloon angioplasty and to determine whether lesion morphology had any influence on the mechanism of balloon angioplasty. Thirty three (15 stable and 18 unstable) patients undergoing single lesion percutaneous transluminal coronary angioplasty were studied with intravascular ultrasound before and after intervention. All examinations, recorded on S-VHS video tape, were studied off-line and matched sites from the point of minimum lumen area after the procedure and the corresponding site prior to intervention were compared. The morphology of…

medicine.medical_specialtymedicine.diagnostic_testInterventional cardiologybusiness.industryUnstable anginamedicine.medical_treatmentLumen (anatomy)medicine.diseaseAnginaLesionInternal medicineAngioplastyIntravascular ultrasoundmedicineCardiologyThrombusmedicine.symptomCardiology and Cardiovascular MedicinebusinessEuropean Heart Journal
researchProduct

An FFR CT diagnostic strategy versus usual care in patients with suspected coronary artery disease planned for invasive coronary angiography at Germa…

2017

Aim Diagnostic evaluation practices for suspected coronary artery disease (CAD) may vary between countries. Our objective was to compare a CT-derived fractional flow reserve (FFRCT) diagnostic strategy with usual care in patients with planned invasive coronary angiography (ICA) enrolled in the PLATFORM (Prospective Longitudinal Trial of FFRCT: Outcome and Resource Impacts) study at German sites. Methods Patients were divided into two consecutive observational cohorts, receiving either usual care or CT angiography (CTA)/FFRCT. The primary endpoint was the percentage of patients planned for ICA, with no obstructive CAD on ICA within 90 days. Secondary endpoints included death, myocardial infa…

medicine.medical_specialtymedicine.diagnostic_testUnstable anginabusiness.industrySubgroup analysisFractional flow reserve030204 cardiovascular system & hematologymedicine.diseaseSurgeryCoronary artery disease03 medical and health sciences0302 clinical medicineQuality of lifeInternal medicineAngiographymedicineClinical endpoint030212 general & internal medicineMyocardial infarctionCardiology and Cardiovascular MedicinebusinessOpen Heart
researchProduct

Effects of Ciprostene on Restenosis Rate during Therapeutic Transluminal Coronary Angioplasty

1992

Ciprostene, a chemically stable prostacyclin analog was studied for its effects on restenosis in patients with coronary artery disease undergoing therapeutic percutaneous transluminal coronary angioplasty (PTCA). In a double-blind, randomized trial 32 patients were randomized to receive either ciprostene or the respective placebo. The infusion started intracoronarily at a rate of 40 ng/kg/min 20 min before introduction of the balloon catheter into the coronary artery. Thereafter infusion was continued intravenously for 36 hours at a rate of 120 ng/kg/min and a tapering off period until 48 hours. The quantitative analyses of the degree of coronary artery stenoses on the angiographic films be…

medicine.medical_specialtymedicine.diagnostic_testbusiness.industryUnstable anginamedicine.medical_treatmentBalloon catheterHemodynamicsmedicine.diseaseCoronary artery diseasemedicine.anatomical_structureRestenosisAngioplastyInternal medicineAngiographyCardiologyMedicinecardiovascular diseasesbusinessArtery
researchProduct

2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation

2020

2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation

unstable anginaMyocardial ischaemia[SDV]Life Sciences [q-bio]Vascular damage Radboud Institute for Health Sciences [Radboudumc 16]dual antithrombotic therapyGuidelineheparin030204 cardiovascular system & hematologyPlatelet inhibitionantiplatelet0302 clinical medicineST segmentMedicinedabigatranMyocardial infarctionguidelinesglycoprotein iib/iiia inhibitorsanticoagulationNon-ST Elevated Myocardial InfarctionrivaroxabanComputingMilieux_MISCELLANEOUSreproductive and urinary physiologydiabetesbleedingsbivalirudinatherothrombosiDisease ManagementangioplastyGuidelines • acute cardiac care • acute coronary syndrome • angioplasty • anticoagulation • antiplatelet • apixaban • aspirin • atherothrombosis • betablockers • bleedings • bivalirudin • bypass surgery • cangrelor • chest pain unit • clopidogrel • dabigatran • diabetes • dual antithrombotic therapy • early invasive strategy • edoxaban • enoxaparin • European Society of Cardiology • fondaparinux • glycoprotein IIb/ IIIa inhibitors • heparin • high-sensitivity troponin • minoca • myocardial ischaemia • myocardial infarction • nitrates • non-ST-elevation myocardial infarction • platelet inhibition • prasugrel • recommendations • revascularization • rhythm monitoring • rivaroxaban • stent • ticagrelor • triple therapy • unstable anginaenoxaparinGeneral MedicineClopidogrel3. Good healthearly invasive strategymyocardial infarctiontriple therapy030220 oncology & carcinogenesisHigh sensitivity troponinembryonic structuresCardiologyPlatelet aggregation inhibitorrevascularizationbiological phenomena cell phenomena and immunityCardiology and Cardiovascular MedicineTicagrelormedicine.drugHumanrecommendationAcute coronary syndromemedicine.medical_specialtyaspiringlycoprotein IIb/IIIa inhibitornon-ST-elevation myocardial infarctionapixabanrhythm monitoringEuropean Society of Cardiologyticagrelor03 medical and health sciencesnitrateatherothrombosisbetablockersInternal medicineacute cardiac careminocachest pain unitDiseases of the circulatory (Cardiovascular) systemHumansIn patientAcute Coronary SyndromeclopidogrelUnstable anginaurogenital systemnitratesbusiness.industryfondaparinuxbetablockerArrhythmias Cardiac030229 sport sciencesbleedingmedicine.diseasemyocardial ischaemiaplatelet inhibitionprasugreldiabeteGlycoprotein IIb/IIIa inhibitorsRC666-701bypass surgerySettore MED/11 - MALATTIE DELL'APPARATO CARDIOVASCOLARErecommendationsedoxabanhigh-sensitivity troponinstentbusinessPlatelet Aggregation Inhibitorscangrelor
researchProduct